{"id":"W4205824700","doi":"10.1200/jco.2021.39.15_suppl.2582","title":"Platform trial of ezabenlimab (BI 754091), an anti-PD-1 antibody, in patients (pts) with previously treated advanced solid tumors: Combination with BI 836880, a VEGF/Ang2-blocking nanobody.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Alberta","funders":"","keywords":"Medicine; Cohort; Oncology; Bevacizumab; Internal medicine; Cancer; Chemotherapy; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006680344,0.001219427,0.0009773807,0.0002788821,0.0002793084,0.0008674692,0.0005899792,0.0008569677,0.003960496],"category_scores_gemma":[0.0003998207,0.000365655,0.0007261843,0.0002620041,0.000531223,0.0006270473,0.0004325037,0.00202868,0.0008711175],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008384103,"about_ca_system_score_gemma":0.001546345,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001136331,"about_ca_topic_score_gemma":0.00275045,"domain_scores_codex":[0.9998195,0.00006412967,0.000006100774,0.0000383261,0.00001451526,0.00005748547],"domain_scores_gemma":[0.9996397,0.00003685916,0.00006447188,0.00001840565,0.00001499589,0.0002254932],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8566473,0.03730662,0.008210541,0.0003807533,0.0006283969,0.0002956587,0.000191005,0.002019488,0.0333815,0.0003028395,0.003778834,0.05685715],"study_design_scores_gemma":[0.4517308,0.524719,0.01379957,0.0000271839,0.0003044616,0.0002723716,0.00006349983,0.001457924,0.003532297,0.0002342593,0.003835345,0.00002347333],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9937563,0.0007395424,0.000293871,0.0003110261,0.00007950981,0.001879288,0.00111533,0.00006616825,0.001758922],"genre_scores_gemma":[0.9895273,0.0006361578,0.000993991,0.0006051541,0.000105238,0.00220573,0.002747949,0.00001893736,0.003159568],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003960496,"threshold_uncertainty_score":0.01324916,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05288422157225228,"score_gpt":0.4208904504800132,"score_spread":0.3680062289077609,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}